its staggering what the opportunity is here. Both geographies represent around 35% of the market each.
We went from around 10c to 50c on achieving licesning agreements for 30% of the market as well as positive interim results.
What happens if we get licensing agreements for one, or both USA and China, which individually represent more market opportunity than what we have garnered already.
happy to stick around for as long as possible, full faith in management and the drug
Ann: Dimerix presentation at Bioshares Biotech Summit, page-25
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $211.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $246.4K | 658.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 262775 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 32276 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |